<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Epstein-Barr virus (EBV) is a human herpesvirus that is usually carried lifelong as an asymptomatic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>EBV is the causative agent of <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> and has been linked to the development of several <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumours</z:e>, including B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, certain forms of T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and some <z:e sem="disease" ids="C0205853" disease_type="Neoplastic Process" abbrv="">epithelial tumours</z:e>, such as undifferentiated nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> and a proportion of <z:hpo ids='HP_0012126'>gastric cancers</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> are characterised by the presence of multiple extrachromosomal copies of the circular <z:mp ids='MP_0001799'>viral</z:mp> genome in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells and the expression of EBV-encoded latent genes, which appear to contribute to the malignant phenotype </plain></SENT>
<SENT sid="3" pm="."><plain>An increasing understanding of the function of EBV latent genes and of the nature of the immune response to the virus is providing exciting new possibilities for the treatment of EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>For example, adoptive transfer of virus-specific cytotoxic T lymphocytes has already been of value in the treatment of EBV-positive B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> arising in post-transplant patients, and this approach is currently being investigated in other EBV-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, gene therapy offers the opportunity to deliver agents that might directly interfere with the function of specific EBV genes </plain></SENT>
<SENT sid="6" pm="."><plain>This review summarises the role of EBV in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In particular, it focuses on the latent proteins as a basis for understanding how EBV might contribute to the process of transformation </plain></SENT>
<SENT sid="8" pm="."><plain>Strategies to target EBV in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, potentially providing alternative therapeutic approaches, are also discussed </plain></SENT>
</text></document>